Alpha 2.0
Login Register
» Authors » Takashi Masuko

Takashi Masuko

Explore the profile of Takashi Masuko including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 87
Citations 1882
Followers 0
Related Specialties
Oncology
Biochemistry
Chemistry
Top 10 Co-Authors
Kazue Masuko
Shogo Okazaki
Hideki Yagi
Tadashi Kusama
Hideyuki Saya
Yasuo Kizawa
Kazuei Igarashi
Shiho Ueda
Osamu Nagano
Reiko Sugiura
Published In
Cancer Sci
Neurosci Lett
PLoS One
Biochem Biophys Res Commun
Genes Cells
Affiliations
Soon will be listed here.
Recent Articles
1.
CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb
Nakano T, Okita K, Okazaki S, Yoshimoto S, Masuko S, Yagi H, et al.
FEBS Open Bio . 2025 Jan; PMID: 39757718
Effective therapies have yet to be established for pancreatic ductal adenocarcinomas (PDAC) even though it is the most aggressive cancer. In the present study, PDAC was analyzed using novel rat...
2.
Complete Cure of Inoperable Stage IV Locally Advanced Hypopharyngeal Squamous Cell Carcinoma by an Innovative Combination Cancer Immunotherapy Consisting of Radiation, Immune Checkpoint Inhibitors, and Dendritic Cell Vaccine
Iwasaki T, Yazaki Y, Myojo T, Masuko T, Nishimura T
Cureus . 2024 Oct; 16(9):e69429. PMID: 39411614
We report the case of a 68-year-old man with locally advanced (LA) head and neck cancer (HNC) (LA-HNC). The patient was diagnosed with inoperable stage IVA hypopharyngeal squamous cell carcinoma...
3.
In Silico Analyses of Vertebrate G-Protein-Coupled Receptor Fusions United With or Without an Additional Transmembrane Sequence Indicate Classification into Three Groups of Linkers
Kamiya T, Masuko T, Borroto-Escuela D, Okado H, Nakata H
Protein J . 2024 Apr; 43(2):225-242. PMID: 38616227
Natural G-protein-coupled receptors (GPCRs) rarely have an additional transmembrane (TM) helix, such as an artificial TM-linker that can unite two class A GPCRs in tandem as a single-polypeptide chain (sc)....
4.
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies
Udagawa H, Nilsson M, Robichaux J, He J, Poteete A, Jiang H, et al.
J Thorac Oncol . 2023 Sep; 19(1):106-118. PMID: 37678511
Introduction: NRG1 gene fusions are clinically actionable alterations identified in NSCLC and other tumors. Previous studies have reported that NRG1 fusions signal through HER2 and HER3 but, thus far, strategies...
5.
CD98 regulates the phosphorylation of HER2 and a bispecific anti-HER2/CD98 antibody inhibits the growth signal of human breast cancer cells
Yamasaki A, Maruyama-Takahashi K, Nishida K, Okazaki S, Okita K, Akiyama Y, et al.
Genes Cells . 2023 Feb; 28(5):374-382. PMID: 36811310
Human epidermal growth factor receptor (HER) family proteins are currently major targets of therapeutic monoclonal antibodies against various epithelial cancers. However, the resistance of cancer cells to HER family-targeted therapies,...
6.
Dual-targeting therapy against HER3/MET in human colorectal cancers
Yamasaki A, Miyake R, Hara Y, Okuno H, Imaida T, Okita K, et al.
Cancer Med . 2023 Feb; 12(8):9684-9696. PMID: 36751113
Background: Colorectal cancer (CRC) is the most common malignancy in the world, and novel molecular targeted therapies for CRC have been vigorously pursued. We searched for novel combination therapies based...
7.
In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized Cu-Intraperitoneal Radioimmunotherapy against Peritoneal Dissemination of Pancreatic Cancer: A Feasibility Study
Hihara F, Matsumoto H, Yoshimoto M, Masuko T, Endo Y, Igarashi C, et al.
Int J Mol Sci . 2022 May; 23(10). PMID: 35628616
Peritoneal dissemination of pancreatic cancer has a poor prognosis. We have reported that intraperitoneal radioimmunotherapy using a Cu-labeled antibody (Cu-ipRIT) is a promising adjuvant therapy option to prevent this complication....
8.
Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain
Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, et al.
Sci Transl Med . 2022 Feb; 14(632):eaax7706. PMID: 35171652
Cancer-specific cell surface antigens are ideal therapeutic targets for monoclonal antibody (mAb)-based therapy. Here, we report that multiple myeloma (MM), an incurable hematological malignancy, can be specifically targeted by an...
9.
Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs
Okita K, Imai K, Kato K, Sugiura R, Endo Y, Masuko K, et al.
Biochem Biophys Res Commun . 2021 Sep; 576:59-65. PMID: 34482024
HER1-and HER2-targeted drugs are effective in cancer therapy, especially against lung, breast and colon malignancies; however, resistance of cancer cells to HER1-and HER2-targeted therapies is becoming a serious problem. The...
10.
Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target
Hayashi N, Yamasaki A, Ueda S, Okazaki S, Ohno Y, Tanaka T, et al.
Oncotarget . 2021 Jul; 12(13):1256-1270. PMID: 34194623
L-type amino acid transporter 1 (LAT1)/SLC7A5 is the first identified CD98 light chain disulfide linked to the CD98 heavy chain (CD98hc/SLC3A2). LAT1 transports large neutral amino acids, including leucine, which...